Met Non Small Cell Cancer Registry (MOMENT)

Launched by EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC. · May 11, 2022

Keywords

ClinConnect Summary

The MOMENT clinical trial is a global study designed to gather important information about people with advanced non-small cell lung cancer (NSCLC) who have a specific genetic change known as METex14. This trial aims to understand how different treatments are working and to see how patients respond to their therapies over time. By collecting detailed information about participants' health, treatment choices, and outcomes, researchers hope to improve our understanding of this type of cancer and its treatments.

To be part of this study, participants need to be adults with advanced NSCLC (stages IIIB-IV) and have confirmed METex14 genetic changes. They should also be starting or currently receiving treatment for their cancer. However, those already taking part in another clinical trial cannot join this registry. Participants will regularly provide information about their health and treatment, helping to create a clearer picture of how to best manage this challenging condition. This is an exciting opportunity to contribute to cancer research and potentially improve future treatments for others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who signed ICF
• • Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
• • Participants who are starting or are already being treated with systemic therapy
• Exclusion Criteria:
• • Participants who are enrolled in a clinical trial